XTX Topco Ltd Purchases New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

XTX Topco Ltd purchased a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 15,795 shares of the company’s stock, valued at approximately $72,000.

Other institutional investors have also bought and sold shares of the company. BNP Paribas Financial Markets acquired a new stake in Verve Therapeutics in the 4th quarter valued at $50,000. KFG Wealth Management LLC acquired a new stake in Verve Therapeutics in the 1st quarter valued at $46,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Verve Therapeutics in the 1st quarter valued at $47,000. Palumbo Wealth Management LLC acquired a new position in Verve Therapeutics in the first quarter worth $72,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Verve Therapeutics in the first quarter worth $83,000. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

Shares of VERV opened at $11.13 on Friday. Verve Therapeutics, Inc. has a 12-month low of $2.86 and a 12-month high of $11.40. The firm has a market capitalization of $992.13 million, a PE ratio of -5.27 and a beta of 2.23. The stock’s fifty day simple moving average is $10.55 and its 200-day simple moving average is $7.29.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. The business had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Jefferies Financial Group lowered Verve Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $28.00 to $11.00 in a research note on Wednesday, June 18th. Lifesci Capital lowered Verve Therapeutics from a “strong-buy” rating to a “hold” rating and set a $12.00 price objective on the stock. in a research note on Wednesday, June 18th. Wall Street Zen raised Verve Therapeutics to a “hold” rating in a research note on Saturday, July 26th. William Blair lowered Verve Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Tuesday, June 17th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $13.50 price objective (down previously from $20.00) on shares of Verve Therapeutics in a research note on Friday, June 27th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Verve Therapeutics presently has an average rating of “Hold” and an average price target of $14.57.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.